...
首页> 外文期刊>Journal of the American Society of Nephrology: JASN >Kidney Allograft and Patient Survival in Type I Diabetic Recipients of Cadaveric Kidney Alone Versus Simultaneous Pancreas/Kidney Transplants: A Multivariate Analysis of the UNOS Database
【24h】

Kidney Allograft and Patient Survival in Type I Diabetic Recipients of Cadaveric Kidney Alone Versus Simultaneous Pancreas/Kidney Transplants: A Multivariate Analysis of the UNOS Database

机译:肾脏的同种异体移植和尸体的I型糖尿病患者单独胰脏/肾脏移植的生存率:UNOS数据库的多元分析

获取原文

摘要

ABSTRACT. Simultaneous pancreas-kidney transplant (SPK) is now a common treatment for insulin-dependent diabetic patients with end-stage renal disease. Renal graft survival rates after SPK have been less well studied. This study compared the kidney survival results for 3642 SPK and 2374 cadaveric renal transplants (CRT) in type I diabetic patients at 112 US transplant centers reported to UNOS during 1994 through 1997. The analysis included follow-up information through September 2000. The kidney graft survival rates were significantly lower among recipients of CRT compared with SPK recipients (P 0.001). Patients who received SPK were younger, less often sensitized, transplanted after shorter periods on dialysis, and less often black. The donors of SPK organs were younger, more often died from head trauma, were less often female, and more often black. SPK renal grafts were transplanted with a shorter cold ischemia time to more poorly HLA-matched recipients. After adjustment of these and other factors, whether a patient was recipient of CRT or SPK was not associated with increased risk of kidney graft failure or patient death. SPK recipients experienced half the rate of delayed kidney function (11% versus 23%) but nearly double the rate of rejections during the initial hospitalization (15% versus 9%) compared with CRT recipients. SPK was associated with better renal allograft survival compared with CRT, despite a higher rate of renal allograft rejection. This observation was explained by favorable donor and recipient factors in the SPK group. After controlling for these factors, SPK provided no protective or detrimental effect on short-term renal allograft or patient survival. E-mail: bunnapradist@cshs.org
机译:抽象。现在,胰腺-肾脏同时移植(SPK)是患有终末期肾病的胰岛素依赖型糖尿病患者的常见治疗方法。 SPK后的肾移植存活率尚未得到很好的研究。这项研究比较了1994年至1997年期间向UNOS报告的112个美国移植中心在I型糖尿病患者中进行的3642个SPK和2374个尸体肾移植(CRT)的肾脏存活结果。该分析包括截至2000年9月的随访信息。 CRT接受者的生存率显着低于SPK接受者(P <0.001)。接受SPK的患者年龄较小,致敏性较低,经过较短时间的透析后即可移植,而黑人则较少。 SPK器官的捐献者年龄较小,死于头部外伤的次数更多,女性较少,黑人较多。将SPK肾移植物以较短的冷缺血时间移植到更差的HLA匹配受体。在调整了这些因素和其他因素之后,患者是否接受CRT或SPK都不会增加肾移植失败或患者死亡的风险。与CRT接受者相比,SPK接受者的肾功能延迟率是其一半(11%对23%),但在首次住院期间的排斥率却几乎翻了一番(15%对9%)。尽管肾移植排斥反应的发生率较高,但与CRT相比,SPK与更好的肾移植存活相关。 SPK组中有利的供体和受体因素可以解释这一观察结果。在控制了这些因素之后,SPK对短期肾移植或患者生存期没有提供保护或有害作用。电子邮件:bunapradist@cshs.org

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号